In Brief: SensorMedics
This article was originally published in The Gray Sheet
Executive Summary
SensorMedics: Plans to meet with FDA in September to discuss civil penalty actions pending against the company. The firm intends to argue for waiver of proposed penalties totaling $2 mil. SensorMedics says FDA's charges should be dropped because the nine devices originally cited as violating premarket requirements no longer are on the market, having been replaced by next-generation products. In addition, the firm maintains that modifications it made to its devices were not subject to 510(k) requirements because they did not affect safety and effectiveness. Earlier this year, FDA waived penalties against Lexicor, citing corrective actions the company had taken and the firm's inability to pay the proposed fines ("The Gray Sheet" Aug. 12, p. 6)...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.